Last reviewed · How we verify
NCT03885167: SCA3
Identification of Biomarkers in Spinocerebellar Ataxia 3
trial testing Specimen Collection in Spinocerebellar Ataxia Type 3 in 22 participants. Completed in 4 January 2023.
4 January 2023
Quick facts
| Lead sponsor | University of Michigan |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 22 |
| Start date | 21 February 2019 |
| Primary completion | 4 January 2023 |
| Estimated completion | 4 January 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Specimen Collection
Conditions studied
- Spinocerebellar Ataxia Type 3 — all drugs for Spinocerebellar Ataxia Type 3 →
Sponsor
University of Michigan
Who can join
18 and older, any sex, with Spinocerebellar Ataxia Type 3. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to examine the differences in cerebral spinal fluid (CSF) and blood of patients with spinocerebellar ataxias and healthy volunteers. The goal of this project is to identify new biomarkers that are useful for characterizing spinocerebellar ataxias and identify targets for treatment or prevention of this condition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03885167
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Specimen Collection
Trials testing the same drug.
- NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting
- NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
- NCT06894745 — PET [89Zr]DFO-starPEG in Solid Tumors · Phase 1 · recruiting
- NCT04713657 — Beta-blocker Administration for Cardiomyocyte Division · Phase 1 · recruiting
- NCT04706481 — Archival of Human Biological Samples in CU-Med Biobank · recruiting
Other recruiting trials for Spinocerebellar Ataxia Type 3
Currently open trials in the same condition.
- NCT05822908 — A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD · Phase 1, PHASE2 · recruiting
Other University of Michigan trials
Trials by the same sponsor.
- NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation · NA · not yet recruiting
- NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD) · NA · not yet recruiting
- NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness · NA · not yet recruiting
- NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health · NA · not yet recruiting
- NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03885167 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Michigan
- Last refreshed: 22 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03885167.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing